Genmab A/S
GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$51.35+0.38 (+0.75%)
Close on Nov 19, 2026
Genmab A/S 7.250% Senior Unsecured Notes due 2033 by Quarter
7.250% Senior Unsecured Notes due 2033 ($M)
Genmab A/S 7.250% Senior Unsecured Notes due 2033: $953M in Q3 2026.
Latest, Q3 2026
953
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
3
Documents cited below
Where the Q3 2026 figure comes from
“|| Ending Balance as of 9/30/2026 | $ | 926 | $ | 1,674 | $ | 1,439 | $ | 953 | $ | 4,992”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 7.250% Senior Unsecured Notes due 2033 ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 953 | – | Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗ |
| Q2 2026 | Jun 30, 2026 | 952 | – | Genmab Form 6-K — H1 / Q2 2026 Interim Report (Six Months Ended Jun 30, 2026) ↗ |
| Q1 2026 | Mar 31, 2026 | 952 | – | Genmab Form 6-K — Q1 2026 Interim Report (Three Months Ended Mar 31, 2026) ↗ |
| Q4 2025 | Dec 31, 2025 | 957 | – | Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗ |
Cite this data
StockData. (2026). Genmab A/S 7.250% Senior Unsecured Notes due 2033 ($M), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/debt-unsecured-notes
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?